Fennec Pharmaceuticals Inc.: An Emerging Biopharmaceutical Company Providing Innovative Treatments Fennec Pharmaceuticals Inc., previously known as Adherex Technologies Inc., is a notable biopharmaceutical company, headquartered in Research Triangle Park, North Carolina. Established in 1996, the company has been relentlessly working towards providing innovative treatment solutions for pediatric cancer patients. Fennec Pharmaceuticals' portfolio includes PEDMARK, a revolutionary formulation of sodium thiosulfate designed to prevent platinum-induced ototoxicity hearing loss in young cancer patients. The company's products are marketed worldwide through a network of pediatric oncology specialists and medical science liaisons, facilitating the availability of cutting-edge treatments to children in need. Fennec Pharmaceuticals' commitment to pediatric cancer treatment has propelled its growth and reputation in the biomedical field. The company's enduring efforts towards making its products accessible to larger populations have brought hope, comfort, and healing to young patients and their families.
Fennec Pharmaceuticals's ticker is FENC
The company's shares trade on the NASDAQ stock exchange
They are based in Research Triangle Park, North Carolina
There are 1-10 employees working at Fennec Pharmaceuticals
It is http://fennecpharma.com
Fennec Pharmaceuticals is in the Healthcare sector
Fennec Pharmaceuticals is in the Biotechnology industry
The following five companies are Fennec Pharmaceuticals's industry peers: